Liquidia Technologies

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Liquidia Technologies sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 1 currently recruiting 2 completed later-stage tilt upper quartile by trial count

Liquidia Technologies: 6 sponsored US clinical trials, 1 recruiting.

Liquidia Technologies sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 4 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Pulmonary Hypertension, with 1 trials.

Upper-quartile sponsor footprint

Liquidia Technologies sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

NCT07285655
ACTIVE NOT RECRUITING

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

NCT06129240
ACTIVE NOT RECRUITING Phase 3

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

NCT04691154
ACTIVE NOT RECRUITING Phase 3

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

NCT03992755
COMPLETED Phase 3

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
COMPLETED Phase 1

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001

NCT01224262

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 4

Therapeutic Areas

Primary Pulmonary Hypertension 1
Pulmonary Hypertension Due to Lung Diseases 1
Pulmonary Arterial Hypertension 1
Influenza 1
Pulmonary Hypertension 1
Interstitial Lung Disease 1

Where Liquidia Technologies enrollment is open (later-stage tilt)

1 recruiting of 6 indexed (17% open); 2 completed (33%).

Phase mix: 4 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Primary Pulmonary Hypertension (1 trial), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Liquidia Technologies: open-pipeline peers nationwide

Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Liquidia Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 468101214 0%20%40%60%80% Total trials Recruiting share Liquidia Technologies23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAdageneAgendiaAkamis BioAngiodynamics
Liquidia Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Liquidia Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Liquidia Technologies page

6 registered trials is a research-attention snapshot, not an endorsement of Liquidia Technologies or any single study.

  • 1 of Liquidia Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Primary Pulmonary Hypertension is the condition Liquidia Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Pulmonary Hypertension trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Liquidia Technologies pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.